Trial Profile
Ixazomib for Treatment of Chronic Graft vs. Host Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 27 Sep 2018 Status changed from active, no longer recruiting to completed.
- 12 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Jan 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.